key: cord-0984151-t0kum2ws
authors: Qing, Enya; Li, Pengfei; Cooper, Laura; Schulz, Sebastian; Jäck, Hans-Martin; Rong, Lijun; Perlman, Stanley; Gallagher, Tom
title: Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
date: 2022-04-19
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110786
sha: 14af149e6960c9ddc96387f6d71f97aa2a53aa1c
doc_id: 984151
cord_uid: t0kum2ws

SARS-CoV-2 continues to evolve into variants of concern (VOCs), with greatest variability in the multidomain, entry-facilitating spike proteins. To recognize the significance of adaptive spike protein changes, we compared variant SARS-CoV-2 virus particles in several assays reflecting authentic virus-cell entry. Virus particles with adaptive changes in spike amino-terminal domains (NTDs) were hypersensitive to proteolytic activation of membrane fusion, an essential step in virus-cell entry. Proteolysis was within fusion domains (FDs), at sites over 10 nm from the VOC-specific NTD changes, indicating allosteric inter-domain control of fusion activation. In addition, NTD-specific antibodies blocked FD cleavage, membrane fusion, and virus-cell entry, suggesting restriction of inter-domain communication as a neutralization mechanism. Finally, using structure-guided mutagenesis, we identified an inter-monomer beta-sheet structure that facilitates NTD-to-FD transmissions and subsequent fusion activation. This NTD-to-FD axis that sensitizes viruses to infection and to NTD-specific antibody neutralization provides new context for understanding selective forces driving SARS-CoV-2 evolution.

Even with available vaccines, antiviral treatments, and mitigation measures, SARS-CoV-2 36 continues to spread through human populations, with adaptive viruses becoming increasing 37 transmissible and potentially able to resist vaccine-induced immunity. Highly contagious variants of 38 concern (VOCs) emerge, first D614G, then   and  variants. Conceivably a genetically stable 39 J o u r n a l P r e -p r o o f variant with maximum transmissibility into both naïve and immunized humans will eventually 40 predominate (Burioni and Topol, 2021 ), yet this is not certain, making for current missions to predict 41 ongoing SARS-CoV-2 evolutionary trajectories. Aims are in place to identify transmissibility 42 determinants in past and current VOCs and further elucidate VOC resistance to vaccine antibodies and 43 antiviral agents. This study addresses a part of these aims by assessing VOC responses to host 44 transmissibility determinants and by explicating antibody neutralization mechanisms. To address neutralization mechanisms, we first considered whether NTD antibodies interfere 110 with an S1-S2 separation process that is traditionally taken as a measure of host cell receptor-induced 111 conformational changes in CoV spike proteins (Gallagher, 1997; Matsuyama and Taguchi, 2009; Walls et 112 al., 2019) . This postulated antibody-mediated interference with S1-S2 stability was prompted by our 113 prior discovery that the SARS-CoV-2 NTD "supersite" loops controlled S1 shedding from VLPs (Qing et al., 114 2021) . SARS-2 VLPs were incubated with mAb 4A8, with or without soluble sarbeco (hACE2) receptors, 115 using soluble embeco (mCEACAM) receptors as negative controls. VLPs were then pelleted free of shed 116 S1 and evaluated for S1-S2 ratios ( Fig. 2A ). As expected, hACE2 but not mCEACAM receptors caused S1 117 shedding (Fig. 2BC) . Notably, 4A8 mAbs did not suppress the hACE2-induced shedding (Fig. 2BC with hACE2 + EVs is associated with proteolysis at the well-characterized S2' position . 124

With 4A8 mAb in the VLP-EV fusion reactions (Fig. 3A) , S2' cleavages were notably suppressed (Fig. 3B) , 125 clearly distinct from control isotype Fc proteins that exerted no effect on S2' cleavage ( Fig. S1) . 126

Reduced S2' cleavage correlated precisely with diminished membrane fusion (Fig. 3C ). An 127 independently identified NTD antibody TRES328 (Peter et al., 2021) phenocopied 4A8 in S2' cleavage 128 and fusion inhibition (Fig. S2) , suggesting a common neutralization mechanism for the NTD antibodies. 129

Replacement of the VLPs with authentic SARS-CoV-2 (D614G) particles gave similar results showing that 130

We also determined whether the relays from NTDs to S2' cleavage sites are present in SARS-CoV 133 spikes. Here we spliced the SARS-CoV-2 NTD loops into SARS-CoV spikes, effectively constructing the 134 SARS-CoV-2 antigenic supersite onto SARS-CoV ( , see Fig S3) . VLPs with these 135 engineered SARS-CoV spikes elicited membrane fusions that were effectively suppressed by 4A8 mAbs, 136 while fusions generated by standard SARS-CoV VLPs were unaffected (Fig. 4AB ). Membrane fusion 137 levels correlated precisely with the extents of S2' cleavage (Fig. 4CD) . These results suggest that the 138 communications between NTDs and S2' cleavage sites are conserved in the sarbecoviruses, and that 139 neutralizing antibodies interfere with NTD mobility such that fusion domains remain uncleaved and 140 incompetent in virus entry. 141

In pre-fusion spike trimers, the NTD antigenic supersites are about 10 nm from the nearest S2' 143 cleavage sites (Fig. 5A) . Furthermore, NTDs are not present in currently available post-fusion spike 144 trimer structures (Cai et al., 2020; Liu et al., 2020) , and so it is not obvious how NTD positioning or 145 restricted NTD mobility might expose or conceal a distal protease substrate site. To gain insights into 146 the structures linking NTD position to S2' cleavage, we used molecular genetic approaches, asking 147 whether SARS-CoV-2 spike variations might promote or impede NTD mAb neutralization. We started 148 with naturally occurring variations. These included a D614G substitution that stabilizes SARS-CoV between NTDs and S2' cleavage sites and noted a beta sheet comprised of strands from two adjacent 165 monomers; residues 701-705 (green) adjacent to residues 787-790 (magenta) with inter-monomer 166 stabilization achieved by A701/N703 interactions with I788 (Fig. 5D ). These strands are near the S2' 167 cleavage sites (Fig. 5A) . We introduced beta strand-disrupting A701P and N703P substitutions into VLPs. 168

Here, VLPs with these substitutions were nearly 10-fold more sensitive to mAb 4A8 neutralization (Fig.  169   5D ). This hypersensitivity to NTD mAb neutralization suggested that the proline substitutions facilitated 170 NTD-driven S2' cleavage and fusion activation. Using trypsin titrations to assess fusion triggering, we 171 found that the A701P/N703P VLPs were indeed activated for fusion at trypsin levels that were nearly 10-172 fold lower than WT VLPs ( Fig. 5D and S6 ). These findings identify an intermonomer beta sheet "linker", 173 between NTDs and FDs, that is involved in transmitting NTD ligation signals to FDs. The results further 174 document a remarkable concordance between NTD mAb neutralization sensitivity and proteolytic 175 triggering of viral membrane fusion. 176

The NTD changes in variants of concern increase sensitivity to protease-triggered membrane fusion 177

In SARS-CoV-2 variants of concern (VOCs), there are substitution mutations in RBDs, in S1-S2 178 furin cleavage sites, in fusion domains, and notably also in the NTDs ( we hypothesized that the NTD changes adapt SARS-CoV-2 for higher sensitivity to proteolytic activation. 186

We incorporated the NTD mutations of five VOCs (α, β, γ, δ and ; see Fig. 6A and S7) into the D614G 187 ("WT") spike background and generated VOC spike-containing VLPs. We then utilized cell-free VLP-EV 188 fusion assays to identify requirements for protease-triggered membrane fusion. Relative to the "WT" 189 VLPs, all five VOC VLPs were hypersensitive to trypsin protease -triggered fusion (Fig 6B-G) . The neutralization mechanisms were elucidated using a tractable in vitro virus-cell membrane 212 fusion system that reflects authentic SARS-CoV-2 entry . Using this system, we 213 demonstrated that NTD antibodies did not interfere with virus binding to hACE2 receptors, nor did they 214 suppress an S1-S2 separation process that arises subsequent to hACE2 binding ( The in vitro fusion system revealed a striking concordance between S2' cleavage and membrane fusion 217 ( Fig S8) , making it abundantly clear that the essential requirement for virus fusion and cell entry is in 218 liberating the S2' transmembrane cleavage fragment. Corroborating these results, the NTD antibodies 219 effectively neutralized authentic SARS-CoV-2 by suppressing S2' proteolytic cleavages ( Fig. 1A and 3DE) . 220

Of note, these findings are consistent with a model in which receptor-bound spikes undergo activating 221 S2' cleavages while S1 remains attached to viruses, with a near end-stage S1 separation occurring 222 regardless of whether the spikes execute productive membrane fusion. This is distinct from previous 223 models depicting viruses engaging receptors and then undergoing complete separation from S1 224 fragments to reveal underlying S2 domains, which are then cleaved at S2' to allow for spike refolding in 225 concert with virus-cell membrane fusion (Jackson et al., 2022; Peng et al., 2021) . 226

The revised entry model prompted us to identify structural elements communicating a 227 suppressive signal from S1 NTDs to S2 fusion domains. One of three elements evaluated was a beta 228 sheet spanning two spike monomers (Fig. 5D ). Disrupting this beta sheet with proline substitutions 229 heightened virus sensitivity to NTD antibody neutralization and to protease-activated membrane fusion. 230

This interdomain beta sheet element may be one of several hubs controlling responses to signals 231 emanated by NTD-or RBD-binding ligands. These signal transducing elements may be central to 232 sarbecoviruses, as S2' cleavage and membrane fusion by the related SARS-CoV spikes were also 233 suppressed by NTD ligation (Fig. 4) . Importantly, the NTDs of several coronaviruses are bona-fide 234 with NTD dynamics suppressed viral fusion, we asked whether VOC NTD changes are adaptive in entry 253 processes, and we found that NTD changes from α-, β-, γ-, δ-and  VOCs all increased virus sensitivity 254 for proteolytic activation of membrane fusion (Fig. 6B-G) . Therefore, we suggest that the NTD 

Only two NTD-specific antibodies were evaluated in this study. Whether additional neutralizing 273 antibodies operate by suppressing proteolytic activation of membrane fusion remains to be determined. 274

An NTD-to-FD axis was recognized in this study, yet NTD variations may also control NTD-to- . NTD neutralizing antibodies does not affect spike S1-S2 stability. 307 (A) Schematic for VLP S1-retention assay. SARS-2 VLPs were pre-incubated with 4A8 and/or hACE2-Fc, or 308 mCEACAM-Fc (not depicted) for 24 h at 37°C. VLPs were subsequently purified through 20% sucrose, 309 and solubilized for Western Blot analysis of spike components. 310 (B) Western Blot analysis of the resulted samples from VLP S1-retention assay. Sample for each 311 condition was split into two halves, one half was probed with anti-S1 antibody while the other half with 312 anti-S2 antibody. Uncleaved S (SUNC), S1, and S2 are labeled. 313 (C) Experiment from panel b was repeated three times, and the S1-S2 ratios (relative to vehicle control) 314 were compared. Mean and standard error (SE; N=3) are graphed. Significance was determined by one-315 way analysis of variance and multiple comparisons using Sidak test. ns, not significant; *, p < 0.05. 316 Gallagher (tgallag@luc.edu). 384

All materials generated in this study will be made available on request by the Lead Contact. 386

• All data reported in this paper will be shared by the lead contact upon request. 388

• This paper does not report original code. 389

• Any additional information required to reanalyze the data reported in this paper is available 390 from the lead contact upon request. 391 

HiBiT-N tagged VLPs were produced as described previously Qing et al., 2021) . Cell-free fusion assays were performed as described previously . Briefly, at 458 4°C, equal volumes of HiBiT-N VLPs and hACE2-LgBiT EVs were mixed with nanoluc substrate (cat#N2420, 459 Promega) and trypsin (Sigma; 10 ng/µl or as indicated) in 384-well multiwell plates. Sample plates were 460 then loaded into a Glomax luminometer maintained at 37°C. Nluc accumulations were recorded over 461 time. VLP-EV cell-free fusions were quantified as the fold increase of Nluc signal from S-bearing VLPs 462 over the signal from spikeless (No S) VLP background control. 463

For antibody neutralization assays, VLPs were incubated with serial dilutions of either 4A8, 464 mCEACAM-Fc, or TRES328 for 30 min at 37°C before adding hACE2-LgBiT EVs, substrate, and trypsin. For 465 proteolytic activation assays, VLPs were incubated with hACE2-LgBiT EVs for 30 min at 37°C before 466 adding substrate and serial dilutions of trypsin. 467 VLP S1-retention assay 468 SARS-CoV-2 S (D614G) VLPs were incubated with vehicle or 4A8 (400 nM) for 30 min at 37°C. Then 469 vehicle, hACE2-Fc (400 nM), or mCEACAM-Fc (400 nM) were added and the mixtures were incubated for 470 24 h at 37°C. After incubation, the VLPs were density purified from the mixture through a 20% sucrose 471 cushion (SW60, 35000 rpm, 2 h, 4°C). The resulted pellets were resuspended and each split into two 472 halves, one half was probed with anti-S1 antibody while the other half with anti-S2 antibody. S1-S2 473 ratios were calculated from the Western blot band intensities. 474

VLPs bearing SARS-2-S (D614G) or SARS-1/2-S, or recombinant SARS-CoV-2 (D614G) were incubated with 476 vehicle, 4A8 (500 nM), mCEACAM-Fc (500 nM), or TRES328 (500 nM) for 30 min at 37°C. Subsequently, 477 EC50 values from each biological replicate were pooled, and subsequently normalized to their 501 corresponding WT spike control, whose IC50 or EC50 values were set to one. Mean and SEM are shown 502 based on data from biological repeats. 503

For instances where only one pair of conditions were compared, statistical analyses were done using 504 one-sample t-tests. For instances where multiple pairs of conditions were compared, one-way analysis 505 of variance followed by the appropriate post hoc tests were applied. Tests used for each data set are 506 specified in the figure legends. All graphs and statistical analyses were completed using Prism 8 507 (GraphPad). P-values less than 0.05 were considered statistically significant. 508 509 Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang 

Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of 512 COVID-19

The SARS-COV-2 Spike Protein Binds Sialic Acids and 515 Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Has SARS-CoV-2 reached peak fitness

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

Distinct conformational states of SARS-CoV-2 spike protein

Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations 529 Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status -Oregon and 530

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a 534 single supersite

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. 585

SARS-CoV-2 evolution during treatment of chronic infection

SARS-CoV2): Evaluation Using Virus-Like Particles. 591 Cells

Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

Lectins enhance SARS-CoV-2 infection and influence neutralizing 597 antibodies

Vaccination Status and the Detection of SARS-CoV-2 Infection in Health Care Personnel Under 600 Surveillance in Long-term Residential Facilities

The 603 Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET

Two-step conformational changes in a coronavirus envelope 606 glycoprotein mediated by receptor binding and proteolysis

N-terminal domain antigenic mapping reveals a site of vulnerability for 610 SARS-CoV-2

Physiological and molecular triggers for SARS-CoV membrane 612 fusion and entry into host cells

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among 615 health care workers in long-term care facilities: a prospective cohort study

Single-cell meta-analysis of SARS-CoV-2 entry genes 619 across tissues and demographics

Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and 622 susceptibility in smokers

Impact of Delta Variant and Vaccination on SARS-CoV-2 Secondary 625 Attack Rate Among Household Close Contacts

Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin

Proteolytic 631 processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism

The SARS-CoV-2 variant, Omicron, shows rapid replication in human 635 primary nasal epithelial cultures and efficiently uses the endosomal route of entry

The furin cleavage site in the SARS-CoV-2 spike protein is required 639 for transmission in ferrets

Cell entry by SARS-CoV-2

A pair of noncompeting neutralizing human monoclonal 644 antibodies protecting from disease in a SARS-CoV-2 infection model

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 648 neutralization

Systematic analysis of SARS-CoV-2 infection of an ACE2-651 negative human airway cell

Distinct Roles for Sialoside and Protein 653 Receptors in Coronavirus Infection

Dynamics 655 of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains

Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor 659 for host adaption

Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for 662 viral entry

Cell entry mechanisms of 664 SARS-CoV-2

Community transmission and viral load kinetics of 667 the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a 668 prospective, longitudinal, cohort study

Neutralizing and protective human monoclonal antibodies 671 recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Detection of a SARS-CoV-2 variant of concern in South Africa

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on 678 Transmissibility and Pathogenicity

Structure, Function, 680 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Unexpected Receptor Functional Mimicry Elucidates Activation of 684

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other 687 sarbecoviruses

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to 693 use ACE2 receptors from additional species

HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant 700 antigenic change, vaccine escape and a switch in cell entry mechanism

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A 706 non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 707 and circulating variants

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike 710 Protein Variant

Structural impact on SARS-CoV-2 spike protein by D614G substitution

SARS-CoV-2 spike-protein D614G mutation increases virion 716 spike density and infectivity

Emergence 718 of a Novel SARS-CoV-2 Variant in Southern California

hACE2-LgBiT EVs were added and incubated for 30 min at 37°C. Lastly, titrated levels of trypsin were 478 added and incubated for 30 min at 37°C. A portion of the resulting mixture was mixed with Nluc 479 substrate and fusion was measured by ways of RLU. SDS-solubilizer was added to the rest of the mixture 480for Western blot analysis. 481Fc constructs 482 pCEP4-mCEACAM-Fc was constructed previously (Gallagher, 1997). pCEP4-hACE2-Fc was generated 483 using the strategy described in (Qing et al., 2020) . Briefly, the mCEACAM coding region was removed by 484NotI and MreI digestion, and replaced with hACE2 ectodomain (codons 1-740). The expression plasmids 485were LipoD-transfected into HEK293T cells, and transfected cells were incubated in FBS-free DMEM 486 containing 2% (wt/vol) Cell Boost 5 (Hyclone). Conditioned media were collected on days 4 and 7, 487